Dompé gains EC approval for rare eye disease drug

Privately-held Italian company Dompé has had its marketing authorization application of cenegermin eye drops for the treatment of moderate to severe neurotrophic keratitis approved by the European Commission (EC).

It is the first biologic approved in the European Union for this condition, a rare and severely debilitating eye disease that can cause vision loss. Until now, there have been no approved drugs for patients affected.

"The next steps will definitely be to make the product available in other areas outside of Europe and in other future indications"